Retinitis Pigmentosa Clinical Trial
Official title:
Extended Pilot Study to Evaluate Pattern Recognition With a Chronic Retinal Implant System
Investigate whether blind subjects that fulfil the patient criteria provided with a Retinal Implant are able to differentiate between simple patterns like horizontal bar, vertical bar and cross.
Status | Active, not recruiting |
Enrollment | 20 |
Est. completion date | December 2010 |
Est. primary completion date | November 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 30 Years to 79 Years |
Eligibility |
Inclusion Criteria - Age between 30 and 79 years at the date of enrollment - Normal hearing and linguistic understanding (with hearing aids if - necessary and in the language of the hospital or in English) - Ability to understand the study and procedures involved - Willingness to participate and comply with follow-up procedures - Good general health based on investigator's opinion - Ability to undergo surgery using general anaesthesia - Signed informed consent - RP, choroideremia, or rod cone dystrophy - Visual field less than 40 ° (if measurable) - Visual acuity not better than (1/50), (logMAR=1.7) - Visual function stable for a duration of at least one year (according to subject statement) - Normal eye pressure (9-21 mmHg) - Bulbus length (AP) between 21 and 25 mm Exclusion Criteria - Allergic response to multiple antibiotics - Known allergies to materials of the implant - Known carrier of multi-resistant organisms - Pregnancy or lactating - History of epileptic seizures - Having active implantable devices (or need within the next 3 years) - Patients with cancer or patients received cancer therapy within the last 2 years - Currently undergoing psychiatric treatment without expert opinion approving participation on the study - Patients having insufficient mental capacity - Neurological diseases, in particular those affecting nerve conduction velocities - Patients currently taking medications affecting brain function - Immunosuppressive subjects |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Intelligent Medical Implants GmbH |
Hornig R, Laube T, Walter P, Velikay-Parel M, Bornfeld N, Feucht M, Akguel H, Rössler G, Alteheld N, Lütke Notarp D, Wyatt J, Richard G. A method and technical equipment for an acute human trial to evaluate retinal implant technology. J Neural Eng. 2005 Mar;2(1):S129-34. Epub 2005 Feb 22. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Investigate whether blind subjects that fulfill the patient criteria provided with a Retinal Implant are able to differentiate between simple patterns like horizontal bar, vertical bar and cross. | 18 months | No | |
Secondary | Secondary goals of this study phase are: Further evaluation of stimulation parameters, Light localization with use of camera, Safety verification of stimulation parameters | 18 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
Completed |
NCT04983914 -
Retrospective NIS to Evaluate the Patient Benefit of TES
|
||
Recruiting |
NCT03845218 -
Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
|
||
Completed |
NCT00231010 -
Molecular Genetics of Retinal Degenerations
|
||
Active, not recruiting |
NCT04611503 -
PDE6A Gene Therapy for Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Recruiting |
NCT01914913 -
Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Completed |
NCT01949623 -
Biomarkers In Retinitis Pigmentosa (BIRP)
|
N/A | |
Completed |
NCT01835002 -
Transcorneal Electrical Stimulation - Multicenter Safety Study
|
N/A | |
Completed |
NCT00407602 -
Argus® II Retinal Stimulation System Feasibility Protocol
|
N/A | |
Completed |
NCT00515814 -
Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors
|
N/A | |
Completed |
NCT00100230 -
DHA and X-Linked Retinitis Pigmentosa
|
Phase 2 | |
Active, not recruiting |
NCT00378742 -
Repository for Inherited Eye Diseases
|
||
Terminated |
NCT05085964 -
An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
|
Phase 2 | |
Recruiting |
NCT05805007 -
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
|
Early Phase 1 | |
Recruiting |
NCT06291935 -
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
|
Phase 1 | |
Recruiting |
NCT05909488 -
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
|
Phase 2/Phase 3 | |
Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
Completed |
NCT04238858 -
Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa
|
N/A | |
Active, not recruiting |
NCT01680510 -
The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil
|
Phase 1/Phase 2 |